November 30, 2016 - By Ellis Scott
AstraZeneca PLC (LON:AZN) stock “Buy” was reconfirmed by Analysts at Deutsche Bank in an analyst report revealed to clients on Wednesday morning.
Out of 30 analysts covering AstraZeneca PLC (LON:AZN), 13 rate it a “Buy”, 4 “Sell”, while 13 “Hold”. This means 43% are positive. GBX 7000 is the highest target while GBX 3700 is the lowest. The GBX 4911.37 average target is 16.07% above today’s (GBX 4231.5) stock price. AstraZeneca PLC has been the topic of 342 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Barclays Capital maintained the stock with “Equal Weight” rating in Monday, April 25 report. The company was maintained on Friday, January 8 by BNP Paribas. Beaufort Securities maintained the stock with “Hold” rating in Monday, April 11 report. The firm has “Hold” rating by Jefferies given on Monday, June 6. The stock of AstraZeneca plc (LON:AZN) has “Buy” rating given on Monday, January 18 by Deutsche Bank. Jefferies maintained the shares of AZN in a report on Thursday, January 14 with “Restricted” rating. The company was maintained on Friday, March 4 by Liberum Capital. As per Monday, October 19, the company rating was maintained by Natixis. The firm earned “Reduce” rating on Wednesday, September 2 by Kepler Cheuvreux. Citigroup maintained AstraZeneca plc (LON:AZN) on Wednesday, September 23 with “Buy” rating.
About 696,859 shares traded hands. AstraZeneca plc (LON:AZN) has risen 8.10% since May 2, 2016 and is uptrending. It has outperformed by 2.87% the S&P500.
Analysts await AstraZeneca plc (ADR) (NYSE:AZN) to report earnings on February, 2. They expect $0.57 earnings per share, down 39.36% or $0.37 from last year’s $0.94 per share. AZN’s profit will be $1.41B for 11.71 P/E if the $0.57 EPS becomes a reality. After $1.32 actual earnings per share reported by AstraZeneca plc (ADR) for the previous quarter, Wall Street now forecasts -56.82% negative EPS growth.
AstraZeneca PLC is a biopharmaceutical company. The company has a market cap of 53.79 billion GBP. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. It has a 26.96 P/E ratio. The Firm has its activities in over 100 countries.
According to Zacks Investment Research, “AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.”
AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a biopharmaceutical company. The Firm focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Firm has its activities in over 100 countries. The Company’s pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development.
More news for AstraZeneca plc (LON:AZN) were recently published by: Schaeffersresearch.com, which released: “Analyst Downgrades: Panera Bread Co, AstraZeneca plc, and Canadian Solar Inc.” on November 28, 2016. Schaeffersresearch.com‘s article titled: “Analyst Upgrades: Apple Inc., AstraZeneca plc, and Ctrip.com International, Ltd.” and published on November 25, 2016 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott